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Background: Heme Oxygenase-1 (HO-1) plays a pivotal role in determining cell survival particularly after mesenchymal stem cell (MSC) 
transplantation. However, few data exist regarding the enhancement of endogenous HO-1 in terms of MSC survival. Therefore, we examined the 
impact of HMG-CoA inhibitor treatment on expression of HO-1 in MSC and its effect on cell apoptosis to make stress-resistant MSC for cell 
transplantation.
Methods: Bone marrow derived MSCs from rats (mean 250 g) were propagated through 3-5th passage. Expressions of the HO-1 and eNOS mRNA 
in MSC was determined by real-time RT-PCR before and after treatment with pitavastatin (0-5 μM) for 24 hours.
Results: Although MSC was not morphologically changed by pitavastatin treatment, HO-1 expression was significantly increased from 1.1±0.1 to 
1.5±0.3, or by 1.5 times and eNOS expresson was significantly increased from 1.1±0.2 to 1.4±0.2, or by 1.4 times after pitavastatin treatment (5 
μM). Immnocytofluorescence demonstrated that the isolated HO-1 positive MSCs were simultaneously positive for Hoechst 33342, indicating the 
induction of Akt phospholylation by pitavastatin. When MSCs were exposed to H2O2 (400μM) as an oxidative stress, cell death assessed by MTS 
assay was markedly reduced in pitavastatin-treated MSC (18 ± 1%) in comparison with control MSC (42 ± 2%, p<0.05). Interestingly, number of tube 
formation in pitavastatin-treated MSCs (200±30 blanch/well) was greater than that in control MSCs (120±20 blanch/well, p<0.05) with enhanced 
production of VEGF (rate of change: 5% vs.12% to, p<0.05).
Conclusions: These results demonstrate that pitavastatin could improve the survival of MSCs by enhancing the endogenous HO-1 and eNOS 
production probably through Akt phospholyration, and could result in functional augmentation of MSCs such as tube formation. We suggest that the 
pretreatment of cells by pitavastatin may result in improvement of their activities after transplantation.
